Brokerage Firm Rating Update on ImmunoGen (IMGN)

ImmunoGen (IMGN) has an average broker rating of 2.61, which is interpreted as a Hold, as rated by 7 equity analysts. Nonetheless, 2 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 4 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 1 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.

ImmunoGen (IMGN) : The consensus price target for ImmunoGen (IMGN) is $5.9 for the short term with a standard deviation of $2.41. The most optimist securities analyst among the 5 who monitor the stock believes that the stock can reach $9, however, the pessimist price target for the company is $3.


For the current week, the company shares have a recommendation consensus of Buy. Also, Jefferies maintains its view on ImmunoGen (NASDAQ:IMGN) according to the research report released by the firm to its investors. The shares have now been rated Buy by the stock experts at the ratings house. Jefferies lowers the price target from $13 per share to $6 per share on ImmunoGen . The rating by the firm was issued on August 5, 2016.

ImmunoGen (NASDAQ:IMGN): stock was range-bound between the intraday low of $2.7 and the intraday high of $2.942 after having opened at $2.87 on Wednesdays session. The stock finally closed in the red at $2.87, a loss of -3.85%. The stock remained in the red for the whole trading day. The total traded volume was 2,139,512 shares. The stock failed to cross $2.942 in Wednesdays trading. The stocks closing price on Thursday was $2.86.

ImmunoGen, Inc. (ImmunoGen) is a clinical-stage biotechnology company focused on the development of targeted anticancer therapeutics. The Companys clinical and preclinical product candidates are antibody-drug conjugates (ADCs), which is a type of medicine that uses a monoclonal antibody to deliver a therapeutic agent to targeted cells. The Company has three clinical-stage anticancer compounds: mirvetuximab soravtansine (IMGN853), coltuximab ravtansine, IMGN529, and IMGN779. The Companys partners are Amgen Inc., Bayer HealthCare (a subgroup of Bayer AG), Biotest AG, Eli Lilly and Company (Lilly), Novartis Institutes for BioMedical Research, Inc. (Novartis), the Roche Group, Sanofi and Takeda. The Companys collaborative partner compounds include Kadcyla, Indatuximab ravtansine, Isatuximab, Anetumumab ravtansine, AMG 595, AMG 172, SAR566658, SAR408701, LOP628 and PCA062. All of the Companys compounds are ADCs with the exception of isatuximab, which is a therapeutic antibody.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.